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Purpose: To report a patient with avascular bleb after trabeculectomy 
who showed promising results after subconjunctival erythropoietin 
injection. 
Case Report: A 45-year-old woman with the diagnosis of primary 
open-angle glaucoma and history of trabeculectomy three years 
prior was admitted to our center. The corrected distance visual 
acuity (CDVA) was 20/20 in both eyes. Her ocular examination 
revealed an avascular and cystic bleb in the right eye. Seidel test 
was negative while bleb sweating was observed after fluorescein 
staining of the bleb area. Intraocular pressure (IOP) was 5 mmHg 
in the right eye. Erythropoietin (2000 unit in 0.1 ml) was injected 
subconjuctivally around the bleb area in the temporal quadrant. 
Six weeks after the injection, the bleb area just superior to the 
conjunctiva showed an increased fibrosis formation while the IOP 
remained the same as before injection. 
Conclusion: Erythropoietin might play a role in preventing the 
progression of a cystic avascular or hypovascular bleb to a leaking 
bleb.
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Introduction 
Late-Onset bleb leakage, as a result of a thin, 
cystic and avascular bleb remains one of the 
major complications after trabeculectomy 
combined with Mitomycin-C injection. 
Various methods have been proposed for the 
management of bleb leakage 1. However, there 
are no prophylactic methods to prevent the 
progression of a thin avascular or hypovascular 
bleb to a leaking bleb. Recently, erythropoietin 
has been widely used in ophthalmic 
pathologies including management of recent-
onset traumatic, methanol-induced, and non-
arteritic ischemic optic neuropathy 2. We used 
the subconjunctival injection of erythropoietin 
in a thin avascular bleb after trabeculectomy. 
We hypothesized that erythropoietin might 
increase the bleb vascularity which can 
prevent future leakage. 
Case Report
A 45-year-old woman was referred to our clinic 
for the routine follow-up with the diagnosis 
of primary open-angle glaucoma and history 
of trabeculectomy three years prior.  The 
corrected distance visual acuity (CDVA) was 
20/20 in both eyes using a Snellen chart. The 
ocular examination revealed the presence 
of an avascular and cystic bleb in the right 
eye (Figure 1, A and B). Seidel test using 
fluorescein stripe and blue light was negative 
for the possible leakage while bleb sweating 
was observed after fluorescein staining of the 
bleb area. Intraocular pressure measured by 
Goldmann applanation tonometry was 5 mmHg 
in the right eye. Anterior segment examination 
revealed no pathology except a mild cataract. 
Macular examination and optical coherence 
tomography showed no sign of hypotony 
maculopathy. Other ocular examinations of 
the right eye and all examinations of the left 
eye were normal. 
To treat the patient initially one drop of 
povidone Iodine 5 % was instilled in the 
right eye. Then after using topical tetracaine, 
erythropoietin was injected subconjuctivally 
with a dosage of 2000 units in 0.1 mL 
(PDpoetin®, 10,000 IU/0.5 mL, Pooyesh 
Darou Biopharmaceutical Co., Tehran, Iran) 
around the bleb area in the temporal quadrant 
while the patient was sitting behind a slit 
lamp. Topical chloramphenicol was instilled 
after the procedure and was continued every 6 
hours for 1 week. The patient was visited daily 
for one week and then weekly. No leakage was 
found after injection and on the post injection 
visits up to six weeks. No cellular reaction in 
the anterior chamber, sign of episcleritis or 
scleritis was observed. Figure 1 (C and D) 
shows the bleb area 6 weeks after the injection. 
The bleb area just superior to the conjunctiva 
showed an increase in the fibrosis formation 
and a mild increase in bleb vascularity. The 
patient’s IOP remained the same as before 
injection. The present study protocol was 
approved by our local ethics committee and 
adhered to the tenets of the declaration of 
Helsinki. Informed consent was received from 
the patient before starting the treatment.
Discussion 
Our case showed promising results for the use 
of subconjunctival erythropoietin injection as 
a preventive measure in avascular thin blebs 
after trabeculectomy. Both neuroprotective 
and angiogenic effects have been proposed 
for erythropoietin in different pathologies 3. 
The neuroprotective effect occurs through the 
inhibition of apoptosis while the angiogenic 
effects require the presence of erythropoietin 
receptors on the capillary endothelial cells. 
Recently, various studies have reported the 
expression of erythropoietin receptors on 
capillary endothelial cells of many tissues 
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including the conjunctival stroma 2. These 
receptors may stimulate angiogenesis as 
effective as a vascular endothelial growth 
factor 2. Besides the erythropoietin’s role in 
the angiogenesis, collagen deposition which 
leads to fibrosis formation can also be induced 
by erythropoietin 4. Although the angiogenic 
effects have been observed in the present 
study, our result is more in favor of collagen 
deposition induced by erythropoietin as the 
possible mechanism of action. Repeated 
doses of erythropoietin might result in 
further angiogenesis. There is a concern that 
fibrosis formation can lead to bleb failure 
after erythropoietin injection. However, the 
prevention of a bleb leak at the expense of 
bleb failure can reduce the chance of possible 
future endophthalmitis and also the need for 
extra surgeries.
Regarding the safety issues in the present case, 
similar route for erythropoietin injection has 
been used by Resende et al., 5 investigating 
neuroprotective effect of erythropoietin in 
animal models of glaucoma. The authors 
reported the subconjunctival route as a safe 
method of injection with no complications 
Figure 1: A thin bleb with areas of necrosis and avascularity can be seen in part A, and 
with higher magnification in part B. Parts C and D show the same patient six weeks after 
injection of 2000 units of erythropoietin subconjuctivally in the temporal region of the bleb. 
The fibrosis formation is observed in the bleb just superior to the conjunctiva. Increased 
vascularization is also evident in this area of the bleb
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like scleritis or episcleritis, scleral melt, 
conjunctivitis, uveitis and endophthalmitis. 
Furthermore, the erythropoietin dosage used 
in the present study has been safely used in 
intravitreal injection of erythropoietin with no 
sign of retinal toxicity 6. However, the safety 
of subconjunctival injection of erythropoietin 
cannot be inferred solely based on the results 
of the present study and needs larger studies to 
be confirmed. 
To the best of our knowledge, subconjunctival 
erythropoietin has not been used to treat the 
thin blebs with reduced vascularity. Our 
study is limited by its case report nature.  We 
recommend case series with longer follow 
up periods to further investigate the effect of 
erythropoietin on avascular or hypovascular 
blebs. 
Conclusion
Erythropoietin might play a role in preventing 
the progression of a cystic avascular or 
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